Circulating metabolites improve the prediction of renal impairment in patients with type 2 diabetes
Authors' conclusion
Further studies are needed to validate our findings in larger cohorts of different clinical, environmental and genetic background.
Study context
- Population
- Individuals with T2D; 188 serum metabolites assessed for association with kidney function
- Participants
- 849 individuals2 cohorts
- Outcome
- Metabolites associated with low eGFR
Methodological detailsdiscovery and validation samples, follow-up study
- Discovery and validation samples
- Follow-up study
Main finding
As reported in the abstract
Metabolites independently associated with low estimated GFR (eGFR) in discovery sample
10
Confirmed in validation sample
9
OR range per 1SD
1.3-2.4
p value range
1.9×10-2-2.5×10-9
Observational data: associations, not effects.
Further findings
eGFR decline (follow-up)
- Metabolites also associated with eGFR decline (tiglylcarnitine, decadienylcarnitine, total dimethylarginine, decenoylcarnitine, kynurenine)
- 5
- β range
- −0.11 to −0.19
- p value range
- 4.8×10-2 to 3.0×10-3
Prediction of glomerular filtration rate (GFR) decline
- Tiglylcarnitine and kynurenine improved discrimination and reclassification of two clinical prediction models of GFR decline
- all p<0.01
- Tiglylcarnitine and kynurenine captured all the information of the other three markers
Original publication
Circulating metabolites improve the prediction of renal impairment in patients with type 2 diabetes. BMJ Open Diabetes Res Care. Published 21 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →